Brainsway Ltd. (BWAY) AI Stock Summary

Snapshot

BrainsWay is a small, profitable medical device maker growing fast: FY2025 revenue hit $52.2M (up 27%), with a healthy 75% gross margin and $7.6M in net income. It generated $16.4M in free cash flow and holds $62.4M in cash against just $7.1M in debt, a comfortable position. The stock sits in the lower part of its 52-week range, and a P/E isn't available here.

What's Happening Right Now

• Tue 29th Sep '26 · Earnings: H1 2026 revenue hit $32.6M (up 35%) with net profit up 60% to $5.0M; the company is deploying cash into minority stakes in several mental health provider networks.
• Thu 10th Sep '26 · Clinical data: A small 12-patient pilot study showed an 83.3% response rate for Deep TMS in patients with depression and early-stage Alzheimer's, though the device isn't FDA-cleared for that use.
• Wed 9th Sep '26 · Earnings: Q2 2026 revenue rose 35% to $17.1M with net income up 34% to $2.7M; management raised full-year 2026 revenue guidance to $68-70M.
• Thu 27th Aug '26 · Clinical data: A peer-reviewed analysis of 89 patients found a 70% relative reduction in suicidal ideation among depression patients treated with Deep TMS.
• Sat 25th Jul '26 · Investment: BrainsWay made a $3 million minority equity investment in Radial Health as part of a strategy to partner with mental health provider networks.

Bottom Line

BrainsWay is a small medical device company that's both profitable and growing quickly, with revenue up double digits for three straight years and a solid cash cushion. Its most recent quarter beat earnings and revenue estimates, and the company keeps publishing supportive clinical data for its Deep TMS treatment. The business looks healthy, but the stock isn't obviously cheap, and it's trading near its 52-week high, so this isn't a bargain-hunter's setup.